CAG + SMG-1

Description

CAG + SMG-1 (Research Peptide)

Description:
The CAG + SMG-1 Blend is a novel combination of two investigational peptide analogs designed for advanced metabolic and appetite regulation research. CAG, an amylin analogue, works synergistically with CAG, a GLP-1 receptor agonist, to explore potential effects on energy balance, satiety, and body weight modulation in preclinical settings.

By targeting complementary pathways—amylin and GLP-1 receptors—this dual-peptide formulation has demonstrated enhanced potential in scientific models for regulating food intake and promoting metabolic efficiency.

Key Research Points:

• CAG (Amylin Analog): Investigated for its ability to reduce food intake and delay gastric emptying.
• SMG-1 (GLP-1 Analog): Studied for glucose regulation, insulin sensitivity, and appetite suppression.
• Synergistic Action: Research suggests combined use may produce superior outcomes in body weight reduction and metabolic control compared to monotherapy in non-human studies.
• Molecular Formula: Research-grade synthetic peptide blend.
• Appearance: Lyophilized powder for reconstitution.

Storage:

Store lyophilized peptide at –20°C. Once reconstituted, keep refrigerated (2–8°C) and avoid repeated freeze-thaw cycles.

⚠️ Disclaimer:

This product is intended for research use only. It is not for human consumption, diagnostic use, or therapeutic administration. The CAG + SMG-1 Blend is supplied exclusively for laboratory, in vitro, or animal research applications conducted by qualified professionals.

• Not evaluated by the FDA.
• Not intended to diagnose, treat, cure, or prevent any disease.
• Use only under appropriate laboratory conditions and safety protocols.